CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX – Get Free Report) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 1,444,389 shares, an increase of 144,438,800.0% from the July 15th total of 1 shares. Based on an average daily trading volume, of 10,945,936 shares, the days-to-cover ratio is currently 0.1 days.
CNBX Pharmaceuticals Price Performance
Shares of CNBX stock traded up $0.00 during trading hours on Tuesday, hitting $0.00. 4,137,084 shares of the company’s stock were exchanged, compared to its average volume of 30,466,232. CNBX Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.00.
About CNBX Pharmaceuticals
CNBX Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the research and development of synthetic cannabinoid-based drug candidates. The company’s proprietary platform applies medicinal chemistry techniques to design novel small-molecule analogs of naturally occurring cannabinoids, aiming to improve efficacy and safety compared with existing therapies. Its pipeline includes multiple preclinical compounds targeting neuropathic and chronic pain, with a goal of advancing these candidates through IND-enabling studies.
Headquartered in Costa Mesa, California, CNBX Pharmaceuticals collaborates with contract research organizations and academic partners to conduct pharmacology and toxicology studies as well as scale up manufacturing processes.
Featured Stories
- Five stocks we like better than CNBX Pharmaceuticals
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
